Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1)

Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1)

US Patent 12091464 · Granted Sep 17, 2024

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof2025
Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof2025
Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof2025
Antibodies directed against CD1272025
Antibodies directed against CD1272025
Uses of anti-SIRPg antibodies2025
Uses of anti-SIRPg antibodies2025
Uses of anti-SIRPg antibodies2025
Humanized anti-human-PD-1 antibody and methods of using them for cancer treatmen2025
Method effector cells using anti-CD127 antibodies for applications in cell thera2025
Method effector cells using anti-CD127 antibodies for applications in cell thera2025
Anti-SIRPa antibodies and their therapeutic applications2025